Get started
Author

Élise Deluche

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
2023 · Fernanda Mosele, Elise Deluche, et al. · Nature Medicine · 448
PDF
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016
2020 · Elise Deluche, Alison Antoine, et al. · European Journal of Cancer · 200
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
2019 · Ronan Flippot, Cécile Dalban, et al. · Journal of Clinical Oncology · 172
Impact of body composition on outcome in patients with early breast cancer
2017 · Elise Deluche, Sophie Leobon, et al. · Supportive Care in Cancer · 166
PDF
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
2021 · T. Grinda, A. Antoine, et al. · ESMO Open · 154
PDF
Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
2022 · Véronique Diéras, Elise Deluche, et al. · Cancer Research · 111
Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature
2020 · Camille Duhamel, Mirela Diana Ilie, et al. · Journal of Personalized Medicine · 88
PDF
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
2021 · Luc Cabel, Frédérique Berger, et al. · British Journal of Cancer · 64
PDF
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort
2019 · David Pasquier, Amélie Darlix, et al. · European Journal of Cancer · 61
PDF
Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic
2021 · Alexandra Bizot, Maryam Karimi, et al. · British Journal of Cancer · 57
PDF
Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study
2022 · Mirela Diana Ilie, Chiara Villa, et al. · European Journal of Endocrinology · 56
Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers
2019 · Matthieu Dusselier, Elise Deluche, et al. · PLoS ONE · 53
PDF
LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
2022 · M.F. Mosele, A. Lusque, et al. · Annals of Oncology · 52
Impact of body mass index on overall survival in patients with metastatic breast cancer
2020 · Khalil Saleh, Matthieu Carton, et al. · The Breast · 51
PDF
Quality of Life of Patients With Cancer During the COVID-19 Pandemic
2021 · KIM-ARTHUR BAFFERT, TIFFANY DARBAS, et al. · In Vivo · 48
PDF
Psoas muscle index is not representative of skeletal muscle index for evaluating cancer sarcopenia
2023 · Frédéric Pigneur, Mario Di Palma, et al. · Journal of Cachexia Sarcopenia and Muscle · 47
PDF
Home-Based Physical Activity in Patients With Breast Cancer: During and/or After Chemotherapy? Impact on Cardiorespiratory Fitness. A 3-Arm Randomized Controlled Trial (APAC)
2020 · François Vincent, Elise Deluche, et al. · Integrative Cancer Therapies · 43
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
2025 · Barbara Pistilli, Fernanda Mosele, et al. · Nature Medicine · 42
PDF
Assessment of the nutritional status of adult patients with acute myeloid leukemia during induction chemotherapy
2017 · Elise Deluche, Stephane Girault, et al. · Nutrition · 38
CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma
2019 · Elise Deluche, Barbara Bessette, et al. · Cancers · 33
PDF
Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patients
2022 · Camille Tlemsani, Jean-Philippe Durand, et al. · Clinical Nutrition ESPEN · 32
PDF
The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study)
2021 · Bruno Raynard, Frederic Pigneur, et al. · Supportive Care in Cancer · 29
PDF
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial
2021 · Jean Courcier, Cécile Dalban, et al. · European Urology · 27
PDF
KLRC 3, a Natural Killer receptor gene, is a key factor involved in glioblastoma tumourigenesis and aggressiveness
2016 · Mathilde Cheray, Barbara Bessette, et al. · Journal of Cellular and Molecular Medicine · 27
PDF
Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?
2021 · Elise Deluche, Denis Lachatre, et al. · The Breast · 26
Works count: 148
Citation count: 2,606
H-index: 25
I10-index: 44
Year
Topic
Type